MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3389/fimmu.2025.1513716

Медицинская библиотека · Frontiers in immunology · 2025

Comparison of immunotherapy based total neoadjuvant therapy or standard neoadjuvant chemoradiation for locally advanced rectal cancer: a multi-institutional retrospective study.

Zhao Wen, Gao Wenxing, Du Jitao, Li Dingchang, Liu Xianqiang, Chang Zhengyao, Chen Peng, Sun Xu, Zhao Yingjie, Jiao Hanqing, Wan Xiangbin, Dong Guanglong

СтатьяМногоцентровое исследованиеСравнительное исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

Combining radiation therapy with immunotherapy produces a synergistic effect in patients with microsatellite stable/mismatch repair-proficient (MSS/pMMR) locally advanced rectal cancer (LARC). This study aimed to evaluate the long-term outcomes and safety of immunotherapy combined with long-course chemoradiotherapy (ICIs + nCRT) versus immunotherapy combined with total neoadjuvant therapy (ICIs + TNT).

METHODS

This retrospective study collected clinical data of adult patients with clinical T3-4 and/or N1 rectal adenocarcinoma who underwent ICIs + TNT or ICIs + nCRT followed by curative surgery at four medical centers between March 2020 and August 2021. The study compared clinical efficacy, disease-free survival (DFS), overall survival (OS) at 3 years postoperatively, and adverse event.

RESULTS

Among 211 enrolled patients, 89 (42%) received ICIs + TNT, while 122 (58%) underwent ICIs + nCRT, with a median age of 56.0 years (range, 20.0-75.0 years). The ICIs + TNT group had a higher median number of resected lymph nodes (15.0 [range, 4.0-37.0] vs. 13.0 [range, 3.0-33.0], P=0.028) compared to the ICIs+nCRT group. However, the groups had no substantial difference in median operative time. The pathological complete response (pCR) rate was 49.4% (44/89, 95% confidence interval [CI] 39.8%-61.3%) in the ICIs + TNT group compared to 35.3% (43/122, 95% CI 26.8%-44.4%) in the ICIs + nCRT group, respectively, with significant difference (P=0.039). After adjusting for potential confounders, the 3-year DFS rates were comparable between the two groups (84.3% vs. 81.9%; P=0.620), as were the OS rates (94.0% vs. 91.1%; P=0.634). Factors independently associated with poorer DFS included age ≤50 years (P=0.044) and a neoadjuvant rectal (NAR) score ≥8 (P=0.008). Similarly, patients aged ≤50 years (P=0.025) exhibited a trend toward worse OS than those older than 50 years. The safety profiles of the two treatment groups were similar.

CONCLUSIONS

Overall, ICIs + TNT demonstrated therapeutic efficacy and a safety profile comparable to ICIs + nCRT in patients with LARC and MSS/pMMR status. Although ICIs + TNT achieved numerically higher downstaging rates, it was not associated with improved survival outcomes. These findings underscore the importance of refining patient selection criteria and making judicious treatment decisions to enhance the prognosis of individuals with rectal cancer.

Для цитирования: Zhao Wen, Gao Wenxing, Du Jitao, Li Dingchang, Liu Xianqiang, Chang Zhengyao, Chen Peng, Sun Xu, Zhao Yingjie, Jiao Hanqing, Wan Xiangbin, Dong Guanglong. Comparison of immunotherapy based total neoadjuvant therapy or standard neoadjuvant chemoradiation for locally advanced rectal cancer: a multi-institutional retrospective study.. Frontiers in immunology. 2025. DOI: 10.3389/fimmu.2025.1513716.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.